AC Immune SA (NASDAQ:ACIU) Short Interest Up 23.5% in October

AC Immune SA (NASDAQ:ACIU) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 984,500 shares, an increase of 23.5% from the October 15th total of 796,900 shares. Based on an average daily trading volume, of 92,100 shares, the days-to-cover ratio is presently 10.7 days. Approximately 1.6% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ACIU shares. StockNews.com cut AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of AC Immune in a research note on Friday.

Hedge Funds Weigh In On AC Immune

Several institutional investors and hedge funds have recently made changes to their positions in the company. Redmile Group LLC boosted its stake in AC Immune by 0.4% in the 1st quarter. Redmile Group LLC now owns 2,007,031 shares of the company’s stock valued at $5,941,000 after purchasing an additional 7,031 shares during the period. Renaissance Technologies LLC increased its position in AC Immune by 26.4% during the second quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock worth $2,602,000 after acquiring an additional 136,300 shares during the period. Assenagon Asset Management S.A. raised its stake in AC Immune by 294.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock worth $1,755,000 after purchasing an additional 328,312 shares in the last quarter. Geode Capital Management LLC grew its position in shares of AC Immune by 6.4% during the 3rd quarter. Geode Capital Management LLC now owns 58,296 shares of the company’s stock worth $220,000 after purchasing an additional 3,499 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of AC Immune during the 2nd quarter worth approximately $218,000. Institutional investors and hedge funds own 51.36% of the company’s stock.

AC Immune Stock Performance

Shares of ACIU opened at $3.19 on Friday. The firm’s 50-day simple moving average is $3.28 and its 200 day simple moving average is $3.49. The firm has a market cap of $315.62 million, a P/E ratio of -6.93 and a beta of 1.28. AC Immune has a 52 week low of $2.25 and a 52 week high of $5.14.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.